These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31284855)

  • 21. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
    Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
    Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in silico design of bioavailability for kinase inhibitors evaluating the mechanistic rationale in the CYP metabolism of erlotinib.
    Chelli SM; Gupta P; Belliraj SK
    J Mol Model; 2019 Feb; 25(3):65. PubMed ID: 30762124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
    Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
    J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L.
    Koe XF; Lim EL; Seah TC; Amanah A; Wahab HA; Adenan MI; Sulaiman SF; Tan ML
    Food Chem Toxicol; 2013 Oct; 60():98-108. PubMed ID: 23876819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
    Nembri S; Grisoni F; Consonni V; Todeschini R
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay.
    Wang L; Hai Y; An L; Chen J; Liang R; He X
    Bioorg Med Chem; 2017 May; 25(10):2689-2700. PubMed ID: 28372934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
    Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
    J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectroscopic studies and molecular docking on the interaction of organotin antitumor compound bis[2,4-difluoro-N-(hydroxy-⟨κ⟩O)benzamidato-⟨κ⟩O]diphenyltin(IV) with human cytochrome P450 3A4 protease.
    Wei Y; Niu L; Liu X; Zhou H; Dong H; Kong D; Li Y; Li Q
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jun; 163():154-61. PubMed ID: 27049867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
    Mudra DR; Desino KE; Desai PV
    Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
    Liu XJ; Lu H; Sun JX; Wang SR; Mo YS; Yang XS; Shi BK
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):465-8. PubMed ID: 25737032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes.
    Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
    Drug Metab Pharmacokinet; 2013; 28(4):345-55. PubMed ID: 23358262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications.
    Ge GB; Ning J; Hu LH; Dai ZR; Hou J; Cao YF; Yu ZW; Ai CZ; Gu JK; Ma XC; Yang L
    Chem Commun (Camb); 2013 Oct; 49(84):9779-81. PubMed ID: 24026006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4.
    Yuki H; Honma T; Hata M; Hoshino T
    Bioorg Med Chem; 2012 Jan; 20(2):775-83. PubMed ID: 22197672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.
    Mannu J; Jenardhanan P; Mathur PP
    J Mol Model; 2011 Aug; 17(8):1847-54. PubMed ID: 21080015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational insights into the different catalytic activities of CYP3A4 and CYP3A5 toward schisantherin E.
    Xue Y; Li J; Wu Z; Liu G; Tang Y; Li W
    Chem Biol Drug Des; 2019 May; 93(5):854-864. PubMed ID: 30637977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 3A: ontogeny and drug disposition.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidating substrate promiscuity in the human cytochrome 3A4.
    Hayes C; Ansbro D; Kontoyianni M
    J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of isatin on protein-protein interactions between cytochrome b5 and cytochromes P450].
    Ershov PV; Yablokov EO; Mezentsev YV; Kalushskiy LA; Florinskaya AV; Veselovsky AV; Gnedenko OV; Gilep AA; Usanov SA; Medvedev AE; Ivanov AS
    Biomed Khim; 2017 Mar; 63(2):170-175. PubMed ID: 28414290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.